This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT03845296

Conditions

1. Deleterious BRCA1 Gene Mutation
2. Deleterious BRCA2 Gene Mutation
3. Loss of Heterozygosity
4. Lung Non-Small Cell Squamous Carcinoma
5. Recurrent Large Cell Lung Carcinoma
6. Recurrent Lung Adenocarcinoma
7. Recurrent Lung Non-Small Cell Carcinoma
8. Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
9. Stage IV Lung Cancer AJCC v8
10. Stage IVA Lung Cancer AJCC v8
11. Stage IVB Lung Cancer AJCC v8

Interventions

1. Drug: Rucaparib

MeSH:Carcinoma Lung Neoplasms Carcinoma, Non-Small-Cell Lung Adenocarcinoma of Lung Carcinoma, Squamous Cell

HPO:Carcinoma Neoplasm of the lung Non-small cell lung carcinoma Squamous cell carcinoma

Toxicity can be estimated to within 11% with 95% confidence.. Inclusion Criteria: - Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) - Patients must be assigned to S1900A. --- S1900A ---

S1900A biomarker eligibility defined as LOH high and/or deleterious BRCA1/2 mutation is as follows using the Foundation Medicine Inc (FMI) tissue- assay: - LOH; alteration type: loss of heterozygosity (LOH); eligible alteration: Genomic LOH >= 21% - BRCA; alteration type: homologous recombination deficiency (HRD); eligible alteration: Deleterious mutations in BRCA1 or BRCA2 - Patients must not have had prior treatment with any PARP inhibitor, including rucaparib, talazoparib, veliparib, olaparib, or niraparib. --- S1900A ---

For information and a list of PARP inhibitors, please consult the S1900A ? --- S1900A ---

Poly Polymerase Inhibitors, Scott et al., 2015 JCO ref from the link on the S1900A protocol abstract page of the SWOG (http://swog.org) --- S1900A ---

Inclusion Criteria: - Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) - Patients must be assigned to S1900A. --- S1900A ---